Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis.
作者信息
Ohki Takamasa, Sato Koki, Yamagami Mari, Ito Daisaku, Yamada Tomoharu, Kawanishi Koki, Kojima Kentaro, Seki Michiharu, Toda Nobuo, Tagawa Kazumi
机构信息
Department of Gastroenterology, Mitsui Memorial Hospital, Kanda-Izumi-cho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.
出版信息
Clin Drug Investig. 2016 Jan;36(1):93-6. doi: 10.1007/s40261-015-0363-x.
Abstract
摘要
相似文献
1
Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis.
Clin Drug Investig. 2016 Jan;36(1):93-6. doi: 10.1007/s40261-015-0363-x.
2
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Jpn J Clin Oncol. 2014 Aug;44(8):711-7. doi: 10.1093/jjco/hyu068. Epub 2014 May 22.
3
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Oncology. 2014;87 Suppl 1:32-6. doi: 10.1159/000368143. Epub 2014 Nov 22.
4
Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Hepatogastroenterology. 2001 Sep-Oct;48(41):1409-15.
5
Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.
J Vasc Interv Radiol. 2013 Apr;24(4):490-500. doi: 10.1016/j.jvir.2013.01.003. Epub 2013 Mar 7.
6
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8.
7
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
8
Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.
Jpn J Clin Oncol. 2012 Mar;42(3):175-82. doi: 10.1093/jjco/hyr189. Epub 2011 Dec 30.
9
Hepatectomy with chemoembolization for treatment of hepatocellular carcinoma.
Hepatogastroenterology. 2003 May-Jun;50(51):750-5.
10
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Chin Med J (Engl). 2013 Nov;126(22):4270-6.
引用本文的文献
1
Clinical outcomes of hepatocellular carcinoma patients after hepatectomy treated with TACE in combination with sorafenib: a propensity score matched analysis.
Transl Cancer Res. 2023 May 31;12(5):1088-1099. doi: 10.21037/tcr-22-2784. Epub 2023 May 8.
2
Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival.
J Gastrointest Cancer. 2022 Dec;53(4):921-929. doi: 10.1007/s12029-021-00712-z. Epub 2021 Sep 22.
3
High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma.
Mol Clin Oncol. 2020 Jan;12(1):60-68. doi: 10.3892/mco.2019.1949. Epub 2019 Nov 18.
4
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
BMC Cancer. 2017 Sep 12;17(1):645. doi: 10.1186/s12885-017-3545-5.
5
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Adv Ther. 2017 May;34(5):1097-1108. doi: 10.1007/s12325-017-0524-9. Epub 2017 Apr 7.
Zotero 插件